AU2002239264A1 - Tetracyclic derivatives as spla2 inhibitors - Google Patents

Tetracyclic derivatives as spla2 inhibitors

Info

Publication number
AU2002239264A1
AU2002239264A1 AU2002239264A AU3926402A AU2002239264A1 AU 2002239264 A1 AU2002239264 A1 AU 2002239264A1 AU 2002239264 A AU2002239264 A AU 2002239264A AU 3926402 A AU3926402 A AU 3926402A AU 2002239264 A1 AU2002239264 A1 AU 2002239264A1
Authority
AU
Australia
Prior art keywords
spla2 inhibitors
tetracyclic derivatives
tetracyclic
compounds
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239264A
Inventor
Douglas Wade Beight
John David Jandzinski
Michael Dean Kinnick
Ho-Shen Lin
John Michael Junior Morin
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002239264A1 publication Critical patent/AU2002239264A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A novel class of tetracyclic compounds of formula (I) is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
AU2002239264A 2000-12-18 2001-12-06 Tetracyclic derivatives as spla2 inhibitors Abandoned AU2002239264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25639500P 2000-12-18 2000-12-18
US60/256,395 2000-12-18
PCT/US2001/043186 WO2002050029A2 (en) 2000-12-18 2001-12-06 Tetracyclic derivatives as spla2 inhibitors

Publications (1)

Publication Number Publication Date
AU2002239264A1 true AU2002239264A1 (en) 2002-07-01

Family

ID=22972086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239264A Abandoned AU2002239264A1 (en) 2000-12-18 2001-12-06 Tetracyclic derivatives as spla2 inhibitors

Country Status (8)

Country Link
EP (1) EP1349836B1 (en)
JP (1) JP2004523504A (en)
AT (1) ATE329905T1 (en)
AU (1) AU2002239264A1 (en)
CA (1) CA2431721A1 (en)
DE (1) DE60120758T2 (en)
ES (1) ES2264708T3 (en)
WO (1) WO2002050029A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
ID23219A (en) * 1998-04-17 2000-03-30 Lilly Co Eli SUBSTITUTED TRISICLIC
CA2338855A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company Indole spla2 inhibitors

Also Published As

Publication number Publication date
DE60120758D1 (en) 2006-07-27
CA2431721A1 (en) 2002-06-27
WO2002050029A8 (en) 2003-11-13
ES2264708T3 (en) 2007-01-16
WO2002050029A2 (en) 2002-06-27
ATE329905T1 (en) 2006-07-15
WO2002050029A3 (en) 2002-09-06
EP1349836A2 (en) 2003-10-08
EP1349836B1 (en) 2006-06-14
JP2004523504A (en) 2004-08-05
DE60120758T2 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
AU5598398A (en) Pyrroles as sPLA2 inhibitors
AU1621795A (en) 1H-indole-3-glyoxylamide sPLA2 inhibitors
YU20194A (en) 1H-INDOL-3-ACETAMIDES AS INHIBITORS WITH PLA2
WO2002050030A3 (en) Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
ATE326963T1 (en) INDOLE COMPOUNDS AS SPLA2 INHIBITORS
AU5454498A (en) Phenyl glyoxamides as spla2 inhibitors
WO2002050034A3 (en) Tetracyclic carbazole derivates and their use as spla2 inhibitors
ATE312817T1 (en) CYCLOHEPT'BÖ INDOLE DERIVATIVES AS SPLA2 INHIBITORS
AU5873400A (en) spla2 inhibitors
WO2002012249A3 (en) Substituted pyrrole compounds and their use as spla2 inhibitors
AU7053700A (en) Novel spla2 inhibitors
AU2002239264A1 (en) Tetracyclic derivatives as spla2 inhibitors
WO2000037472A3 (en) Substituted pirroloindoles
WO2002050028A8 (en) Substituted benzoindoles as spla2 inhibitors
WO2001049662A3 (en) Carbazole derivatives as inhibitors of spla2
WO2002000641A3 (en) Spla2 inhibitors
AU2002245019A1 (en) Benz(g) indoles and their use as spla2 inhibitors